Cargando…
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
The purpose of the study was to determine toxicity, efficacy and immunologic effects of concurrent subcutaneous injections of low-dose interleukin-2 (LD-IL-2), granulocyte–monocyte colony-stimulating factor (GM-CSF) and interferon-α 2b (IFNα) in progressive metastatic renal cell carcinoma. In a mult...
Autores principales: | Verra, N, Jansen, R, Groenewegen, G, Mallo, H, Kersten, M J, Bex, A, Vyth-Dreese, F A, Sein, J, van de Kasteele, W, Nooijen, W J, de Waal, M, Horenblas, S, de Gast, G C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741048/ https://www.ncbi.nlm.nih.gov/pubmed/12778059 http://dx.doi.org/10.1038/sj.bjc.6600915 |
Ejemplares similares
-
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma
por: de Gast, G C, et al.
Publicado: (2003) -
GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019) -
G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990) -
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
por: Bosteels, Cedric, et al.
Publicado: (2022) -
Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023)